it/its if I don't know you. Alex or Kadir, latine. Throw yourself into the unknown with the pace and a fury defiant. art shop, gallery or donate: ko-fi.com/voidalex 42. queer. ltr with @ballsballsbowls
When my mother forgets a word, she is the queen of coming up with new words. Words that would take a third National Treasure movie to fully decipher. I was talking to her yesterday, and she said this: “You know the time for los jibbities is coming up. You must be so excited!” Oh, is it time for los jibbities already? I must have missed it on my calendar. Are we celebrating something? “Of course! We should all be celebrating, shouldn’t we?” OK, so los jibbities is a happy thing. It’s not like something is giving you the heebie-jeebies, which would have been my one and only guess. “Los heebie-jeebies? Now you’re making things up...and this is my show.” You’re right. The time for los jibbities is coming up. Is this a season? “Yes, the season for love. The season for pride.” OK, los jibbities. “Yeah, sound it out.” Los…jibbities. LGBTs! “Sí, mira cuz you’re gay!” “You couldn’t just say pride season? You couldn’t just… *laughs*
I found these pictures I took of the food (so many generic/store brand packages) at a family gathering 20 years ago, thought they might be somebody's aesthetic today, so I'm releasing them into the public domain.
hey if you're transfem you don't have to call yourself amab just so you know. if you're transmasc you don't have to call yourself afab. if you're nonbinary you don't need to use either. no one needs to know. thats a thing that happened to you once. you wouldn't call yourself a walmart resident because you needed pasta one time and that was the only thing open
For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again
For millions of people managing type 2 diabetes, mornings begin the same way — a needle, a dose, and a quiet mental note to do it all again tomorrow.
That routine just changed.
On March 26, 2026, the U.S. Food and Drug Administration approved Awiqli (insulin icodec-abae), developed by Novo Nordisk, as the first and only once-weekly basal insulin ever approved for adults with type 2 diabetes in the United States.
This is not a minor update to an existing drug.
It is the first entirely new class of basal insulin to reach U.S. patients in more than two decades.
Instead of injecting insulin every single day, people with type 2 diabetes using Awiqli will only need one shot per week, on the same day, every week.
That means reducing from 365 injections a year down to just 52.
For anyone who has ever felt the weight of that daily ritual — the anxiety of forgetting, the physical discomfort, the constant reminder that their body needs help — this approval represents something much bigger than a dosing schedule.
It represents relief.
How the Drug Actually Works
Understanding why this injection lasts a full week requires a quick look inside the body.
Most traditional basal insulins are absorbed into the bloodstream and begin breaking down within 24 hours, which is why patients need a fresh dose every day to maintain stable blood sugar levels.
Awiqli works differently.
Its active ingredient, insulin icodec-abae, is engineered to loosely attach to a blood protein called albumin, which is found naturally and abundantly in the bloodstream.
This attachment creates a slow-release reservoir.
Instead of flooding the system and fading fast, the insulin releases gradually and consistently over an entire seven-day period, keeping blood sugar in a healthy range around the clock...
What Comes Next
Awiqli is not standing alone in this space for long.
Eli Lilly is developing its own once-weekly basal insulin, called efsitora alfa, which is currently in late-stage clinical trials.
If that drug also earns FDA approval, it would give patients and doctors two once-weekly options to choose from, allowing for personalized decisions based on a patient’s health profile, insurance coverage, and individual response.
The broader direction of travel in diabetes care is unmistakable.
Fewer injections, smarter formulations, and better integration with digital tools like continuous glucose monitors and insulin-tracking apps are all converging toward a future where managing diabetes requires less daily mental effort without becoming any less medically precise...
A Small Shot With Large Implications
It is easy to look at a once-weekly injection and see only a scheduling change.
But the science behind Awiqli, the scale of the ONWARDS trials, and the consistent satisfaction reported by patients all point toward something that matters far more than convenience.
Diabetes management has always asked a lot of people.
It asks for daily vigilance, daily discipline, and a daily willingness to confront one’s own condition, sometimes in uncomfortable or inconvenient circumstances.
Anything that reduces that load, without reducing the quality of care, is worth taking seriously.
For the more than 37 million Americans living with diabetes, and the hundreds of millions more around the world, a simpler weekly routine could mean the difference between a treatment plan that works on paper and one that actually works in a person’s life.
That is the real significance of what the FDA approved on March 26, 2026.
Not just a new drug.
A new way of keeping people healthy, one week at a time.
wait you understand that kinks are ok because they're fantasies that make you happy right? you all get that you don't need to have trauma for your kinks to be okay? right? like none of you think i witnessed a tragic accident on the pool toy assembly line right?
like "some people work through their personal issues with kink" was a good first step for some of the class that were struggling but i think now we're ready for "things that don't hurt anyone and make people happy are okay even if you personally think it's icky"
theartofmadeline
germansingergirl
origamiaround
titsay
2087
areudirty
romaincrisis
